Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is -1.87% lower on its value in year-to-date trading and has touched a low of $7.64 and a high of $17.75 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ARQT stock was last observed hovering at around $13.26 in the last trading session, with the day’s gains setting it 0.41%.
Currently trading at $13.67, the stock is 0.21% and -1.40% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.33 million and changing 3.09% at the moment leaves the stock 8.05% off its SMA200. ARQT registered 58.40% gain for a year compared to 6-month gain of 7.72%.
The stock witnessed a -6.63% loss in the last 1 month and extending the period to 3 months gives it a -17.65%, and is -0.44% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.85% over the week and 2.80% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 342 employees, a market worth around $1.63B and $212.82M in sales. Fwd P/E is 69.64. Profit margin for the company is -60.95%. Distance from 52-week low is 79.04% and -22.99% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.35%).
The EPS is expected to grow by 52.31% this year
The shares outstanding are 119.14M, and float is at 104.86M with Short Float at 16.00%.
The top institutional shareholder in the company is JENNISON ASSOCIATES LLC with over 11.57 million shares valued at $107.62 million. The investor’s holdings represent 9.3712 of the ARQT Shares outstanding. As of 2024-06-30, the second largest holder is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares valued at $93.04 million to account for 8.1021 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 9.82 million shares representing 7.95 and valued at over $91.3 million, while FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds 7.1147 of the shares totaling 8.79 million with a market value of $81.7 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
Arcutis Biotherapeutics Inc disclosed in a document filed with the SEC on Jun 13 ’25 that Heron Patrick J (Director) bought a total of 2,646 shares of the company’s common stock. The trade occurred on Jun 13 ’25 and was made at $13.08 per share for $34610.0. Following the transaction, the insider now directly holds 27448.0 shares of the ARQT stock.
Still, SEC filings show that on Jun 04 ’25, Heron Patrick J (Director) acquired 1,890 shares at an average price of $13.32 for $25177.0. The insider now directly holds 24,424 shares of Arcutis Biotherapeutics Inc (ARQT).
